GLA-SE adjuvant

BIOLOGICAL5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network, Worcester HIV Vaccine

Conditions

HIV InfectionsHIV Prevention

Phase 1

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

CompletedNCT03220724

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-08-22End: 2023-03-21Updated: 2026-05-04

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

CompletedNCT03409276

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2018-03-16End: 2020-10-22Updated: 2022-04-25

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

CompletedNCT04607408

HIV Vaccine Trials NetworkHIV Infections

Start: 2020-11-10End: 2024-07-24Updated: 2026-01-29

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

CompletedNCT04927585

Worcester HIV VaccineHIV Infections

Start: 2021-07-08End: 2023-12-07Updated: 2024-04-09

Phase 2

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Not yet recruitingNCT07675629

Worcester HIV VaccineHIV Prevention

Start: 2026-09-01End: 2029-08-01Target: 126Updated: 2026-06-30

Related Papers

Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.

2025-11-10

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Emerging Microbes & Infections2025-04-071 citations

Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns

Journal of Clinical Investigation2025-04-031 citations

Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.

2024-05-017 citations

Development of a platform-based approach for the clinical production of HIV gp120 envelope glycoprotein vaccine candidates

Vaccine2021-06-017 citations